Darwish, Mona
Nunez, Rene
Youakim, James M.
Robertson, Philmore Jr.
Funding for this research was provided by:
ACADIA Pharmaceuticals
Article History
Accepted: 26 October 2023
First Online: 28 November 2023
Declarations
:
: This trial was sponsored by Acadia Pharmaceuticals Inc.
: Acadia Pharmaceuticals Inc. is adhering to current US and EU requirements so will not make individual de-identified participant data available; however, the protocol and statistical analysis plan will be made available upon request to the corresponding author.
: MD, RN, and JMY are employees of Acadia Pharmaceuticals Inc. PR, Jr., is a consultant for Acadia Pharmaceuticals Inc.
: The trial was conducted in accordance with applicable regulations, including the current Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice. All requisite trial-related material, including the protocol, were reviewed by an institutional review board (IntegReview, approval number 4009273) and approved on May 4, 2020.
: All participating subjects provided written informed consent.
: Not applicable.
: Not applicable.
: All authors made substantial contributions to the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.